The stock price of Tandem Diabetes Care is under pressure due to the strength in weight loss drug companies. This is because weight loss drugs can potentially reduce the need for diabetes care products, which is Tandem's main business. The company's presentation at the Wells Fargo Healthcare Conference today could also impact the stock price depending on the information shared.